MELFALAX contains melphalan, an alkylating cytotoxic agent that exerts its antitumor effect by damaging DNA in cancer cells. This leads to inhibition of cell division and ultimately cell death, particularly in rapidly proliferating tissues.
Melphalan is widely used in oncology and is a cornerstone drug in treatment regimens for multiple myeloma and other malignancies.
The drug is recommended for:
Melphalan is a well-established chemotherapeutic agent with decades of clinical evidence supporting its efficacy.
Studies demonstrate:
Melphalan is included in international oncology treatment protocols and widely used in clinical practice worldwide.
The drug is indicated for the treatment of malignant diseases.
Main indications include:
It works by damaging tumor cell DNA, leading to inhibition of cell division and cell death.
The drug is administered intravenously or used as part of specialized chemotherapy regimens under the supervision of an oncologist. The dosage and schedule are individualized based on the type of cancer, disease stage, body weight, and overall patient condition. The solution is prepared immediately before use in a clinical setting. Self-administration is not permitted.
